Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Voyager Therapeutics has received a consensus rating of "Moderate Buy" from nine research firms, with a 12-month average price target of $13.25.
• The company reported a loss of ($0.57) EPS for the last quarter, significantly missing analysts' estimates and noting a revenue of only $5.20 million.
• Recent insider trading saw CFO Nathan D. Jorgensen sell 7,666 shares at an average price of $4.78, reducing his stake in the company.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $13.2471.

VYGR has been the subject of a number of analyst reports. Wedbush cut their price objective on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 15th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th.

Voyager Therapeutics Trading Down 2.9%

VYGR stock opened at $5.00 on Monday. The firm has a 50 day moving average of $3.99 and a 200-day moving average of $3.50. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $8.27. The firm has a market capitalization of $277.35 million, a P/E ratio of -2.70 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. The firm had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million. Sell-side analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total value of $36,643.48. Following the sale, the chief financial officer owned 123,834 shares of the company's stock, valued at $591,926.52. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 6.39% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Voyager Therapeutics by 53.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company's stock valued at $204,000 after acquiring an additional 21,149 shares in the last quarter. Strs Ohio purchased a new stake in shares of Voyager Therapeutics in the 1st quarter valued at about $256,000. Nuveen LLC purchased a new stake in shares of Voyager Therapeutics in the 1st quarter valued at about $368,000. American Century Companies Inc. raised its holdings in shares of Voyager Therapeutics by 7.2% in the 1st quarter. American Century Companies Inc. now owns 131,521 shares of the company's stock valued at $445,000 after acquiring an additional 8,795 shares in the last quarter. Finally, Hsbc Holdings PLC raised its holdings in shares of Voyager Therapeutics by 74.0% during the 1st quarter. Hsbc Holdings PLC now owns 67,903 shares of the company's stock valued at $229,000 after buying an additional 28,878 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.